Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 20;12(4):e057671.
doi: 10.1136/bmjopen-2021-057671.

Efficacy and safety of whole-lung lavage for pulmonary alveolar proteinosis: a protocol for a systematic review and meta-analysis

Shixu Liu #  1 , Xiangning Cui #  1 , Kun Xia  1 , Yuanyuan Duan  1 , Mengran Xiong  1 , Guangxi Li  2
Affiliations

Efficacy and safety of whole-lung lavage for pulmonary alveolar proteinosis: a protocol for a systematic review and meta-analysis

Shixu Liu et al. BMJ Open. .

Abstract

Introduction: Pulmonary alveolar proteinosis (PAP) is an ultrarare disorder characterised by the accumulation of alveolar surfactant and the dysfunction of alveolar macrophages that results in hypoxemic respiratory failure. Whole-lung lavage (WLL) is currently the primary therapy for PAP. However, systematic evaluation of the clinical efficacy of WLL is lacking. We aim to perform a systematic review and meta-analysis of existing evidence to support WLL for the clinical treatment of PAP.

Methods and analysis: We will search the PubMed (MEDLINE), Cochrane Library, Embase, Web of Science and Google Scholar databases from inception to December 2021 for observational studies using WLL for the treatment of PAP. Two authors will independently screen the eligible studies, assess the quality of the included papers and extract the required information. Review Manager V.5.4 will be used to perform the meta-analysis. We will evaluate the overall quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach. All steps of this protocol will be performed using the Cochrane Handbook for Preferred Reporting Items for Systematic Review and Meta-analysis statement.

Ethics and dissemination: This systematic review and meta-analysis will be based on published data. Therefore, ethical approval is not required. We will publish our results in a peer-reviewed journal.

Prospero registration number: CRD42022306221 (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022306221).

Keywords: Bronchoscopy; RESPIRATORY MEDICINE (see Thoracic Medicine); Thoracic medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram of study selection process. PRISMA, Preferred Reporting Items for Systematic Review and Meta-analysis.
See this image and copyright information in PMC

References

    1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958;258:1123–42. 10.1056/NEJM195806052582301 - DOI - PubMed
    1. McCarthy C, Avetisyan R, Carey BC, et al. . Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis 2018;13:129. 10.1186/s13023-018-0846-y - DOI - PMC - PubMed
    1. Iftikhar H, Nair GB, Kumar A. Update on diagnosis and treatment of adult pulmonary alveolar proteinosis. Ther Clin Risk Manag 2021;17:701–10. 10.2147/TCRM.S193884 - DOI - PMC - PubMed
    1. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002;166:215–35. 10.1164/rccm.2109105 - DOI - PubMed
    1. Kumar A, Abdelmalak B, Inoue Y, et al. . Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med 2018;6:554–65. 10.1016/S2213-2600(18)30043-2 - DOI - PubMed

MeSH terms